Compare IZEA & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | IZEA | ATOS |
|---|---|---|
| Founded | 2006 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Advertising | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 78.8M | 83.3M |
| IPO Year | N/A | 2012 |
| Metric | IZEA | ATOS |
|---|---|---|
| Price | $3.89 | $0.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 64.3K | ★ 1.5M |
| Earning Date | 11-12-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $36,176,492.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $15.91 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 7.12 | N/A |
| 52 Week Low | $1.68 | $0.55 |
| 52 Week High | $5.86 | $1.29 |
| Indicator | IZEA | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 26.57 | 51.64 |
| Support Level | $3.86 | $0.60 |
| Resistance Level | $4.01 | $0.66 |
| Average True Range (ATR) | 0.16 | 0.05 |
| MACD | -0.02 | 0.01 |
| Stochastic Oscillator | 4.38 | 64.95 |
IZEA Worldwide Inc offers solutions that range from creator agency services to creator technologies to a marketplace that connects marketers with creators. The Company provides value through managing custom content workflow, creator search and targeting, bidding, analytics, and payment processing. The company also enables creators to monetize their content, creativity, and influence through brands and marketers. The company compensates these creators for producing content, such as long and short-form text, videos, photos, status updates, and illustrations, for marketers or distributing such content on behalf of marketers through their websites, blogs, and social media channels.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.